This may be due to feedback upregulation of the PI3K/Akt pathway in response to MEK inhibition, as Hoeflich et al. [52] has demonstrated that the selective MEK inhibitor PD0325901 enhances PI3K/Akt signaling in several breast cancer cell lines. Here, MAP2K7 is linked to breast cancer.